Attached files

file filename
EX-99.1 - EX-99.1 - Trovagene, Inc.a12-9768_14ex99d1.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 30, 2012

 

Trovagene, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

27-2004382

(State or other jurisdiction

 

IRS Employer

of incorporation or organization)

 

Identification No.)

 

11055 Flintkote Avenue, Suite B

San Diego, CA 92121

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (858) 217-4838

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 8.01        Other Events

 

On May 30, 2012, Trovagene, Inc. (the “Company”) issued a press release announcing (i) the pricing of its public offering of 1,150,000 units (the “Units”) at $8.00 per Unit; (ii) the listing of the Company’s Common Stock on The NASDAQ Capital Market under the symbol “TROV”; and (iii) the effectiveness of the reverse split of the Company’s outstanding common stock on a one-for six basis.  A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

99.1

Press Release dated May 30, 2012

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:         May 30, 2012

 

 

 

TROVAGENE, INC.

 

 

 

 

 

By:

/s/ Antonius Schuh

 

 

Antonius Schuh

 

 

Chief Executive Officer

 

3